Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.045 USD | -2.34% | -8.04% | -25.36% |
09/05 | Transcript : Bluebird bio, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
06/05 | Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.36% | 21Cr | |
+7.30% | 11TCr | |
+11.01% | 11TCr | |
+0.96% | 2.23TCr | |
-12.19% | 2.22TCr | |
-5.52% | 1.94TCr | |
-37.85% | 1.79TCr | |
-5.99% | 1.72TCr | |
+7.05% | 1.43TCr | |
+34.83% | 1.25TCr |
- Stock Market
- Equities
- BLUE Stock
- News bluebird bio, Inc.
- Morgan Stanley Trims Price Target on bluebird bio to $3 From $4, Maintains Underweight Rating